M3, Inc.
Presentation Material
July 2024

Copyright © 2024 M3, Inc. All rights reserved.

0

The following presentation contains forecasts, future plans, managementtargets and other forward-looking projections relating to M3, Inc. and/or
its group. These statements are drawn from assumptions of future
events based on data currently available to us, and there exist
possibilities that such assumptions are objectively incorrect and/or may
produce differing actual results from those mentioned in the statements.
Furthermore, information and data other than those concerning theCompany and its subsidiaries/affiliates are quoted from public information,and the Company has not verified and will not warrant its accuracy or
dependency.
M3, Inc.

Copyright © 2024 M3, Inc. All rights reserved.

1

FY2024Q1 Consolidated Results
Unit: JPY MM

FY2023 Q1

FY2024 Q1

YoY

Revenue

57,39664,209 +12%

Operating
Profit18,004

16,899-6%

Profitbefore tax

19,831

18,784-5%

Profit13,554

12,750-6%

YoY growth inbusiness
excluding COVID
related revenues,
sales +16%

The first half started in line with the expectation ofhigher revenue and lower profit
Copyright © 2024 M3, Inc. All rights reserved.

2

Consolidated Revenue Trend and COVID Impact
Unit: JPY MMCOVID related

64,20956,996
46,403～8,10057,396～1,000～3,000+16%～2,200(clinical trials,
vaccination support,
promotion oftherapeutic drugs andvaccines, etc.)

35,478Regularbusinesses

FY2020Q1

FY2021Q1

FY2022Q1

FY2023Q1

FY2024
Q1

In Q1, negative impact of approx. 2 billion yen was materialized
mainly in the Medical Platform and Evidence Solution segments,
with the possibility of larger negative impact for the full year

FY23 Actuals: Q1 ~3.0 Bn, Q2 ~2.7 Bn, Q3 ~2.7 Bn, Q4 ~2.0 Bn
FY24 Actuals: Q1 ~1.0 Bn

Copyright © 2024 M3, Inc. All rights reserved.

3

FY2024 Q1 Consolidated Results by Segment
Unit: JPY MM

FY2023Q1

FY2024Q1

YoY

Domestic

MedicalPlatform

Revenue

21,947

20,969-4%

Profit

8,904

7,924

-11%

Evidence
Solution

Revenue

6,965

6,108

-12%

Profit

1,885

1,013

-46%

CareerSolution

Revenue

5,588

7,212

+29%

Profit

2,663

3,314

+24%

Site
Solution

Revenue

7,663

10,597+38%

Profit

831

1,342

+62%

Emerging
Businesses

Revenue

552

538

-3%

Profit

-126

143

-

Revenue

15,71519,879+26%

Profit

3,679

3,719

+1%

Overseas

Copyright © 2024 M3, Inc. All rights reserved.

 Revenue +2% excluding
COVID Pharma marketing: The
impact of a decline in COVIDrelated sales became
apparent, but thefundamental DX is still
progressing Other businesses such as DXof the clinical scene showedsteady growth Order backlog: 27.7 Bn
 Lower momentum in orderactivities. Temporary
downtrend due to cyclicalfactors
 Business for physicians andpharmacists both performedwell Additional physician-related
demand driven by overtime
work regulation
 OP more than +25% excluding
US clinical trial business Partly influenced by positive
currency tailwinds
4

FY2024Q1 Forecasts vs. Actuals
Revenue
Initial Forecasts

Operating profit～62.5 Bn

～14.0 Bn

Medical Platform
Evidence Solutions
Career Solutions
Site Solutions
Overseas
Other / Adjustments
FY2024Q1 Act.

64.2 Bn

16.9 Bn

Both revenue and operating profit are off to a solid start, partly
due to the conservative initial forecasts for Medical Platforms,
etc. mainly in the first half of the fiscal year
Copyright © 2024 M3, Inc. All rights reserved.

5

Relationship between Growth Rate and COVID
Organic
Growth Rate

Before COVID

During COVID

Repercussion

Normalized

10km/h

10km/h

10km/h

10km/h

10km/h

10km/h

20km/h

0km/h

COVID-19
Impact10km/h

10km/hIn Total…

Current
Status per
Segment

MPF

CS

ES

SS

Overseas

Currently, each segment and business is in a different
phase, and the outlook for growth rate also varies* MPF: Medical Platform, ES: Evidence Solution, CS: Career Solution, SS: Site Solution
Copyright © 2024 M3, Inc. All rights reserved.

6

M3’s Triple Growth Engine + CSV
1. Ecosystem
Expansion

2. IndividualBusiness
Development(Sagrada Familia)
Regions (12 areas)
７

８

10

11

１

２

３

４

５

６

７

８

９

10

１

11

ＭＰ

Businesses (30 - 50)

CS ＳＳ ＥＳ

OthersOthersBusinesses (30 - 50)

Regions (12 areas)

Regions (12 areas)９ Continuous new
business entries

 Pharma marketing/ Clinical Scene DX

２

３

４

５

６

７

８

９

10

11

ＭＰ

６

CS ＳＳ ＥＳ

５

Businesses (30 - 50)

４Others３

CS ＳＳ ＥＳ

２ＭＰ

１

3. Ecosystem
Synergy
Creation Cross-cell synergy
maximization

4. Social Impact Creation → CSV
Copyright © 2024 M3, Inc. All rights reserved.

7

Growth Engine 1： Ecosystem Expansion(Sagrada Familia)
７８Regions (12 areas)
９

10

11

１

４

５

６

７

８

Regions (12 areas)
９

10

11

１

Businesses (30 – 50)

ＭＰ

３

OthersBusinesses (30 – 50)

CS ＳＳ ＥＳ
Others

２

２

３

４

５

６

７

８

９

10

11

ＭＰ

６

CS ＳＳ ＥＳ

５

Businesses (30 – 50)

４

CS ＳＳ ＥＳ

３ＭＰ

２OthersRegions (12 areas)
１

4. Social Impact Creation → CSV
Copyright © 2024 M3, Inc. All rights reserved.

8

Leverage 3 Major Resources to Solve Healthcare Issues

6.5 mil. registered doctors worldwide

Healthcare
Issues×

Overwhelming
Platform

Top-notch technical professionals

State-of-the-art Technology
Experts from varied fields unite

Problem Solving Skills

Copyright © 2024 M3, Inc. All rights reserved.

9

Business Scope Expansion and Growth Potential
FY： 2010

2015

2020

2023

Country：

3 →8 （2.5x） →11 （3.5x） →17 （5.5x）

Business Types：

6 →

15 （2.5x） →35 （6.0x） →38 （6.0x）

Business Units

：

10 →

24 （2.5x） →56 （5.5x） →73 （7.0x）

Sales (bn)

： 14.6 → 64.7 （4.5x） → 169.2 （12.0x） → 238.9 （16.5x）(Type x Country)

Aggressive M&A to ensue in reaching growthpotentials exceeding 10~20x current levels…
Copyright © 2024 M3, Inc. All rights reserved.

10Trend in M&A Volume: Programmatic M&A Strategy
11

11

5

5

10
3

6

Domestic
Overseas

6

6

7

5
1

FY2021

FY2022

FY2023

FY2024
Q1

M&A is completed with approximately 10 companies annually.
For FY2024 Infrastructure for On Call Cooperation, Medcare, and
MinaCare consolidations were closed. We will continue to pursue
M&A opportunities actively
Copyright © 2024 M3, Inc. All rights reserved.

11Cosmotec：Capital and Business Alliance with Sensome
 Sensome is developing a smart clot-sensing guidewire that improves
thrombectomy surgery for stroke treatment
 Cosmotec obtains exclusive distribution rights in Japan This product enables real-time monitoring of thrombus status and provision ofdata to physicians, a step toward faster and more accurate thrombectomy

Impact on Stroke Treatment*

Current

Expected
Outcome% of New Thrombus**

11％

2％

Ave. Stay in Hospital

9 Days

6 DaysAlmost doubles thrombus removal rate in the first procedure,contributing to improving patient QOL, and reducing medical costs*Reference: https://jnis.bmj.com/content/13/12/1117#T1**If a device that is compatible with thrombus removal is not used, there is a possibility that the thrombus may jump to a new peripheral blood vessel during the surgery and become a new thrombus

Copyright © 2024 M3, Inc. All rights reserved.

12

Growth Image per Business Expansion Phases
Sales Trend (JPY)
Businesses added after FY2023～600 bilBusinesses added between FY2015 and FY2023
Businesses added between FY2010 and FY2015
Business as of FY2010

239 bil～60

15 bil
FY201065 bilAssumption～120

1/4 of existing
businesson top

～155

CAGR
～20%

～210

CAGR
～15%
CAGR
～10%

～110

～33
～31

～70

～115

FY2015

FY2023

Five years fromnow

Simulations updated based on FY2023 results. No change incontinuing to achieve similar business growth as before through new
business development, new business growth, and existing businessgrowthCopyright © 2024 M3, Inc. All rights reserved.

13

Business Expansion Creation Flow

Structural
Differentiation

Reinforcementof Ecosystem

Investment Target
Expansion

Self-reinforcing expansion cycle = "superbly capable staff" basealso expands, and continuity is further strengthened... "businesssnowball" to multiply rapidly
Copyright © 2024 M3, Inc. All rights reserved.

14

Growth Engine 2： Individual Business Development
Regions (12 areas)
７８Regions (12 areas)
９

10

11

１

５

６

７

８

Regions (12 areas)
９

10

11

１

Businesses (30 – 50)

ＭＰ

４

OthersCS ＳＳ ＥＳBusinesses (30 – 50)

３

Businesses (30 – 50)

Others

２

２

３

４

５

６

７

８

９

10

11

ＭＰ

６

CS ＳＳ ＥＳ

５

Businesses (30 – 50)

４

Others３

CS ＳＳ ＥＳ

２ＭＰ

１

4. Social Impact Creation → CSV
Copyright © 2024 M3, Inc. All rights reserved.

15

Pharmaceutical Sales & Marketing DX

Copyright © 2024 M3, Inc. All rights reserved.

16

Pharma Marketing Cost and TAM for M3
10 yearsago

Present

FutureM3’s Role

down by ~300 bn yen
TAM

Industry
productivity
improvementfrom DX

MR
99%
Related1.5 tn yen
Costs

Internet

1%

15 bn yen95%

1.15 tn yen

5%

70 bn yen

70～80%

700～
800 bn yen(2) MR Activity
DX Support

20～30%(1) Internet
MarketingSupport200～
300 bn yen(3) Data-driven
MarketingSupportM3 involvement to go beyond the bounds of the internet
to improve productivity across the entire industry
Ref: M3 survey and estimate; numbers are approximate
Copyright © 2024 M3, Inc. All rights reserved.

17

Trend of Domestic Pharmaceutical Sales Reps (MRs)(10,000)

Historical Peak
65,752 MRs

7-1,095 -522
6-950 -752

46,719 MRs
in FY2023-2,533-2,742(Second largest
decline ever)-3,572
5

4-1,738-2,166-2,9632008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

In addition to a decrease in the number of MRs, an increasing
number of contract reps and online reps who work exclusively
online or by phone.... The trend toward sales efficiency is expected
to continue* Source: MR Certification Center “2024 MR White Paper”

Copyright © 2024 M3, Inc. All rights reserved.

18

Current Status of Pharmaceutical Marketing
Demand and Its Trend
ＣＯＶＩＤ-19

Sales

After COVID

FutureStructural changes

•
•
•

Now

•
Short-term demand•

Advancement of structural
digital transformation (DX)
Further penetration of datadriven marketing
Projects on a larger scale

Temporary decline indemand during the COVID
periodCost reduction at someglobal pharma companies

The impact of the decline of COVID-19 revenue (for vaccines and treatment
drugs) expanded from the initial forecast with the possibility to have anegative impact of approx. 6 billion yen for the full year
Copyright © 2024 M3, Inc. All rights reserved.

19

As a Strategic Partner to Pharma Companies
Efforts for Renewed Growth

Overall Trend
ＣＯＶＩＤ-19

Sales

After COVID

Now

Future Rejuvenate and strengthen leadership Our ProductsContinual development of services
that dramatically improve theproductivity of pharmaceuticalcompany sales and marketing(currently at level 50%)
 Our Professional Staff
Continuously expanding the teamby several tens of people each year
(currently at level 50%)
 Productivity Per Staff
Standardization of service
proposals, skills enhancement,
improvement in per-person
productivity through DX (currently
at level 75%)

Further accelerating essential DX initiatives as a strategic
partner to pharmaceutical companies
Copyright © 2024 M3, Inc. All rights reserved.

20

Professional Staff Fortification Plan
Unit： Index with FY2019 as 100

375~500

Reduce the no. of
external consultants
while increasing theoverall number

100

250

23%

17%

 HR capacity
increase Recruiter
reinforcement(fee scale)

77%

83%

FY2019FY2023

FY2024

Few years
from now…

1

1.6

1.4

1

M3
Employees(pre-COVID)

Cost per
Staff

250

Q1

Temporaryincreasedue tooutsourcing

Q1

Normalizedwith proper
hires

Staff Fortification
Initiatives

Normalizedwith proper
hires New grad
recruitment
fortification
 Improve costs
while increasing
headcount

Professional staffing, +1% in total (+9% for in-house, -26% forexternal), more focusing on strengthening recruitment of immediate
workforce with a greater emphasis on the quality than in the past
Copyright © 2024 M3, Inc. All rights reserved.

21

DX of the Clinical Scene

Copyright © 2024 M3, Inc. All rights reserved.

22

DX of Clinics: Creating a New Patient Experience
Current

Post DX (new patient experience)

AccessLong waiting timein lobbies

Online reservations

Diagnosis

OfflineOnline/Offline Hybrid

Payment

Wait to pay atservice desk

Head straight home(digital payments)

Rx

Local pharmacy

Delivered to homeor officeMedical
Records

Difficult access

Review own healthrecords online

Midnight
Emergencies

Wait until nextmorning

24/7 Online Service

Creating a completely different patient experience through“DigiKar Smart”
Copyright © 2024 M3, Inc. All rights reserved.

23

M3 DigiKar EHR Growth
Number of Sites Using M3 DigiKar

6,450

 Cumulative number of
installations isapproximately 6,450.
Steady progress Co-selling with
DigiKarSmart further
increases the added
value of DigiKar

FY15 16

17

18

19

20

21

22

23

24

Incontestable #1 market share within cloud-based digital healthrecords, approximately 250 million charts
Copyright © 2024 M3, Inc. All rights reserved.

24

DX of Clinics： DigiKar Smart
PhysicalOnlineAppointment

Medical Institutions：Managing System

AutoReception

Next
Appointment

Patients：

M3 DigiKar Smart
Payment

Mobile App
Consultation

Linking to
EHR

31,000 reviews with a rating of 4.6 from users, a new patient
experience created, and a high rating in the category
Taken from the following URL, as of July 18, 2024
https://apps.apple.com/jp/app/m3%E3%83%87%E3%82%B8%E3%82%AB%E3%83%AB%E3%82%B9%E3%83%9E%E3%83%BC%E3%83%88%E8%A8%BA%E5%
AF%9F%E5%88%B8/id1563102530

Copyright © 2024 M3, Inc. All rights reserved.

25

No. of DigiKar Smart Users
Unit: Index with FY2021Q3 as 1

5,673
4,741
4,320

 Users are rapidly
penetrating DigiKar
Smart as the clinic's
infrastructure.
2.7 times higher thanFY23Q1

2,973
2,067

 Video call has been
added and is
expanding as an
infrastructure fortelemedicine

1,368
1,070
1

44 173479

Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1
FY21

FY22

FY23

FY24

* Quarterly sum of monthly UUs
Copyright © 2024 M3, Inc. All rights reserved.

26

Ecosystem Synergy: Medical Data Business
Unit: Index with FY2023Q1 as 100

Sales of Medical Data Business*

134
Approx.

1.3x

100

FY2023Q1

FY2024
Q1

Medical data business (actual medical practice, physician practicestandards, etc.) also grew significantly along with the increase in thevolume of data accumulated. Steady creation of ecosystem synergies* Target: Real World Data, Estimation related services (part of Pharmaceutical Marketing business)
Copyright © 2024 M3, Inc. All rights reserved.

27

Overseas

Copyright © 2024 M3, Inc. All rights reserved.

28

Number of Doctor Members and Panelists (Global)
Ratio of doctor members(As of June 2024)

Including regions not mentioned above, more than 6.5 million
doctor members and panelists, covering over 50% of doctors
worldwide*The no. of doctors in Japan is based on data from the Ministry of Health, Labour and Welfare (2022).
The no. of doctors in other countries is based on the latest data from WHO and other sources.

Copyright © 2024 M3, Inc. All rights reserved.

29

Overseas Segment: Sales by Region
Unit: JPY MM

Growth rate

COVID related
sales within

19,87315,704
North
America

EuropeAPAC+27%*Including approx. 10% of
currency tailwinds

7,746

+21%

6,389
7,811
5,945
3,369

4,316

FY2023Q1

FY2024Q1

+31%
+28%

North America
 Continued strong
performance, including
contribution from Kantar
acquisition
 Clinical trial business:
Strengthening managementbase and muscularization inprogress for recovery ingrowthEurope Steady progress in France andthe UK, benefiting from M&A

ＡＰＡＣ
 Continued solid momentum,
along with DBMCI contributions

Accelerating new initiatives for the future such as M&A andstructural reforms
Copyright © 2024 M3, Inc. All rights reserved.

30

Overseas Growth Trends by Business (FY)
Unit: JPY Bn

Service forDoctors(Platform for doctors in North
America, Europe, and APAC
and EHR)Clinical Trials(M3 Global Research:
Expanding in North America,
Europe, and APAC)(Operation of clinical trials sites
in North America)

Career for
Doctors(Human resources businesscentered on doctors in North
America and Europe)

29
25
19
11

14

25
Approx.

2.6x

9.8

13

16

18

Approx.

2.6x

6.8 7.7

9.3

2.9

19 20 21 22 23

19 20 21 22 23

4.6
Approx.

4.7 5.2

7.5

9.9

12
Approx.

2.6x

1.6x

19 20 21 22 23

19 20 21 22 23

Achieve growth trends in various business types* Based on each subsidiary's principal business, aggregated by fiscal year
Copyright © 2024 M3, Inc. All rights reserved.

31

Growth Engine 3： Ecosystem Synergy Creation
Regions (12 areas)
７８Regions
Regions (12 areas)
areas)
９

10

11

１

４

５

６

７

８

Regions (12 areas)
９

10

11

１

ＭＰ

Businesses (30 – 50))
Others３

OthersCS ＳＳ ＥＳBusinesses (30 – 50)–
50

Businesses (30 – 50)

Businesses (
30

２

２

３

４

５

６

７

８

９

10

11

ＭＰ

６

CS ＳＳ ＥＳ

５

Businesses (30 – 50)

４

Others３

CS ＳＳ ＥＳ

２ＭＰ

１

4. Social Impact Creation → CSV
Copyright © 2024 M3, Inc. All rights reserved.

32

Business Scope Expansion and Growth Potential

FY： 2010

2015

2020

2023

Country：

3 →8 （2.5x） →11 （3.5x） →17 （5.5x）

Business Types：

6 →

15 （2.5x） →35 （6.0x） →38 （6.0x）

Business Units

：

10 →

24 （2.5x） →56 （5.5x） →73 （7.0x）

Sales (bn)

： 14.6 → 64.7 （4.5x） → 169.2 （12.0x） → 238.9 （16.5x）(Type x Country)

Copyright © 2024 M3, Inc. All rights reserved.

33

Cross-Business Synergy Creation Potential
１

２

３

４

0

1

3

6

・・・

ｎ

Number ofbusinesses

Synergy
Links

nC2

Synergy potential between businesses: 73Ｃ2 = 2,628
possible linkages
Copyright © 2024 M3, Inc. All rights reserved.

34

Ecosystem Synergy Value Creation
Unit: Index with FY2023Q1 as 100

Growth rate

116

COVID
Non-COVID100

FY2023 Q1RegularBusiness

Approx.

1.3x

Overall
Approx.

1.2x

FY2024 Q1

The next ten years will be based on ecosystem synergies, includinginternal and external collaborations, to further promote healthcare
problem-solving/social impact creation and business expansion*Sum of value additive projects spanning across multiple business lines and data utilization. Definitions will be reviewed as necessary, including this time
Copyright © 2024 M3, Inc. All rights reserved.

35

“The White Jack Project”
Pre-Onset/
Healthy Person
General Public(consumer)

After Onset/
Patient

Future expanding
priority areas

Phase 1 Happiness-i
Phase 2

Rinkai
MedicalPhase 3CancerPrevention

Phase 4 ＥＢＨＳ

HCP(e.g. wholesaler)

Traditional main
business domain

Phase 5Phase 6 Medcare
Phase 7 MinaCare

Steady progress is also being made on the White Jack project,which realizes M3's mission from a more upstream perspective
Copyright © 2024 M3, Inc. All rights reserved.

36

Expand Coverage of Enterprise Services
Number of Employees Covered byEnterprise Services
Unit: 10,000 persons

263

Covers approximately 2.5
million employees in
FY24Q1, with the following
services

24Q1

 EBHS Life
 Cancer prevention, PSP Ask Doctors
 Booking & conducting
medical check-ups
 Employee health data
management
 Dispatch of industrial
physicians and stresschecks Services for healthinsurance associations

203
Approx.

200x

78
1
FY19

18

19

20

21

22

23

Steadily expanding the business base to create ecosystem synergies aswell… With the consolidation of Medcare and MinaCare, coverage has
spread to health insurance associations, surpassing 2.5 million
employee coverage
Copyright © 2024 M3, Inc. All rights reserved.

37

Consolidation of MinaCare
Main Services
 Aiming to actualize"investment-based
medicine" that
promotes the
avoidance of disease
and invests inmaintaining andimproving health MinaCare's CEO, Dr.
Yamamoto, is to join
M3 as Chief Healthcare
OfficerBusiness support services forhealth insurance associations
Covers approx. 50 associations andapprox. 3 million members

Data business for healthcarerelated companies
Analyzed data from over 10 million people
based on medical expertise

Further expand services and coverage for health insurance
associations to accelerate the White Jack Project, promoting
mutual cross-selling and new service development
Copyright © 2024 M3, Inc. All rights reserved.

38

Social Impact Creation
Regions (12 areas)
７８Regions
Regions (12 areas)
areas)
９

10

11

１

５

６

７

８

Regions (12 areas)
９

10

11

１

Businesses (30 – 50)

ＭＰ

４

OthersCS ＳＳ ＥＳBusinesses (30 – 50))
Others３

Businesses (30 – 50)–
50

Businesses (30 – 50)

Businesses (
30

２

２

３

４

５

６

７

８

９

10

11

ＭＰ

６

CS ＳＳ ＥＳ

５

Businesses (30 – 50)

４

Others３

CS ＳＳ ＥＳ

２ＭＰ

１

4. Social Impact Creation → CSV
Copyright © 2024 M3, Inc. All rights reserved.

39

SDGs and CSV: M3's CSV positioning
ＣＳＶ

ＳＤＧｓ
Sustainable Development Goals

Creating Shared Value

International objectives thatgovernments, businesses, andindividuals in all countries aim toachieve with regard to human rights,
the environment and development

Initiatives by companies to solve
social problems through their corebusiness

Positioning for
Companies

Each company fulfills its
responsibilities toward internationaltargets

Balancing corporate growth andsolving social issues

Relevance toCorporate
MissionNot necessarily linked to thecompany's mission

Fully consistent with corporate
mission/purpose(Development goals which are possible to sustain)

Detail(Creation of shared values)

Under M3’s mission of “Making use of the Internet to increase, as much as possible,
the number of people who can live longer and healthier lives, and to reduce, as muchas possible, the amount of unnecessary medical costs,” we are also committed to
SDGs through its CSV activities

Copyright © 2024 M3, Inc. All rights reserved.

40

M3’s CSV* Impact (1/2): Patients/End Users
Providing a Seamless Healthcare Experience
Number of medical consultations using Digikar Smart: 5.6 million perannum, more than 5 times compared to the previous year
Reduction of 1.68 million hours spent in clinics
Including the above, 35.4 million hours of patient waiting time reducedby the M3 group… approximately 4,000 years or the life expectancy of
50 persons**
FY2023, from a group total of about 34 million receptions

Professional Advice Provision for Health Concerns
Offering physician answers online to daily health concerns; ~320,000
posted questions gathering over 79 million UU views annually
FY2023Granting Wishes for Severely Ill Patients
44 wishes granted through the CaNoW program;over 1.5 million PVs of videos and articles documenting the grants
As of April 2024, since the service launch in 2019

Support for corporate health management and employee healthpromotion
Accelerate efforts in pre-symptomatic state and preventive medicine,with approximately 2 million employees covered
FY2023* CSV = Creating Shared Value ** Calculated based on the average life expectancy of Japanese men and women as of 2023, quoted from the following URL
https://www.mhlw.go.jp/toukei/saikin/hw/life/life22/index.html, as of April 18, 2024
Copyright © 2024 M3, Inc. All rights reserved.
41

M3’s CSV* Impact (2/2): Medical Professionals
Information Provision for all HCPs

Approximately 11 million viewers in total for web
conferences, etc.
FY2023

Medical Examination Support

Supporting medical examinations through the
management of information across 300 million
electronic health records, domestically and abroad
As of FY2023

Productivity Improvement for Pharma Companies

Distribution of 110 million e-details = workload of
55,000+ MRs (more than the total number of MRs in
Japan)FY2023

Actualizing M3’s mission across various areas, to reduce
unnecessary medical costs and to support healthier lives using
digital technologies* CSV = Creating Shared Value
Copyright © 2024 M3, Inc. All rights reserved.

42

FY2024 Outlook

Copyright © 2024 M3, Inc. All rights reserved.

43

Annual Results and Forecasts
Revenue

Operating Profit

Unit: JPY MM

Unit: JPY MM

273,000~268,000

Operating profit*
Medlive IPO Impact

238,883

95,141

230,818
208,159

71,983 70,000~67,000

64,210 64,381

169,198

57,972130,973
113,059
94,471
78,14364,66051,34636,75914,646 26,007
8,534
19,0402,276 5,729
891
7,475 11,811
3,854
1,563
480
107

46 255 509 895

FYE
00 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

(6m)

-93

34,33730,80027,48625,05020,022
16,061
7,648 13,738
4,803
9,294
6,031
1,683 3,597
3,990
2,677

FY
E
00 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24(6m)

In line with tradition, aim to expand our business foundation
and achieve growth from a medium to long-term perspective*FY2021 excludes gains related to China IPO

Copyright © 2024 M3, Inc. All rights reserved.

44